New drug firsekibart aims to tame lupus flares in Hard-to-Treat patients

NCT ID NCT07381465

Ongoing Disease control Sponsor: Chinese SLE Treatment And Research Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This pilot study tests Firsekibart, a biologic that blocks IL-1, in 15 adults with mild to moderate lupus who still have symptoms despite standard therapy. Participants receive three shots over 8 weeks, then stop the drug to see if symptoms return. The goal is to see if this approach can reduce disease activity safely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Firsekibart (an IL-1 inhibitor biologic drug given as a shot)
What this could lead to: If it works, this could offer a new treatment option for lupus patients with fever and inflammation who don't respond to standard therapies.
What could go wrong: This is a very small pilot study with only 15 people, no placebo group, and early results may not apply to all lupus patients. The drug is also stopped after 12 weeks to see if symptoms return.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS ERYTHEMATOSUS, SYSTEMIC

Contacts and locations

Locations

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.